Sector News

Categories

Borderless Insights

Image
The Skills-Forward Revolution:   Stretching the Boundaries of Professional Flexibility
Image
Sustainability: Business Leaders Must Secure the Long-Term Strategy Despite Short-Term Pressures
Image
Negotiating Terms with a New Employer

Pfizer has $33B and the M&A world at its feet

January 26, 2015
Life sciences
Pfizer, which spent much of last year trying to acquire U.K. giant AstraZeneca, is now sitting on about $33 billion in cash, and the company’s deal pedigree has analysts dreaming of major M&A down the line.
 
As Bloomberg notes, that war chest will certainly be a topic of conversation when Pfizer presents its fourth-quarter and full-year results on Tuesday. But until then–and, likely, afterward–it’s anyone’s guess just what the U.S.’s largest drugmaker plans to do with its money.
 
Dissecting Pfizer’s last major overture, the failed $118 billion bid for AstraZeneca, the company was primarily concerned with two things: a U.K. address that could reduce its tax burden and an entry into the blockbuster world of immunotherapies for cancer. Pfizer made up ground on the latter score largely through a roughly $2.9 billion deal with Merck KGaA signed in November, but it remains stuck with a U.S. tax bill.
 
That means it may make another run at Actavis, an Irish-headquartered company whose price tag just got a lot steeper thanks to a $66 billion acquisition of Allergan. Analysts have also bandied about Mylan, Valeant Pharmaceuticals and even GlaxoSmithKline among potential targets.
 
But changing political winds have made such tax-saving moves, called inversions, more difficult and less lucrative, especially for high-profile companies like Pfizer. And, as Thrivent Financial analyst David Heupel told Bloomberg, the company is unlikely to make a big, risky gambit on a high-dollar target.
 
“They’re looking for strategic assets and they’re taking a pretty broad stroke as to what they’re looking at,” Heupel told the news service. “But I think they’re going to take a diligent and disciplined financial approach, and I don’t think that’s going to equate to a lot of opportunity for them.”
 
By Damian Garde
 

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

Read more
July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

Read more
July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

Read more
More news

How can we help you?

We're easy to reach